ARCA BIOPHARMA INC (ABIO) Stock Price, Forecast & Analysis
USA - NASDAQ:ABIO - US00211Y5069 - Common Stock
ABIO Key Statistics, Chart & Performance
The current stock price of ABIO is 2.4 USD. In the past month the price decreased by -22.83%. In the past year, price increased by 16.57%.
ABIO Latest News, Press Relases and Analysis
ABIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.94 | 382.94B | ||
| AMGN | AMGEN INC | 14.63 | 172.20B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.02 | 106.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.31 | 68.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 852.08 | 56.96B | ||
| ARGX | ARGENX SE - ADR | 62.07 | 51.25B | ||
| INSM | INSMED INC | N/A | 39.50B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.19 | 35.30B | ||
| NTRA | NATERA INC | N/A | 27.44B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.86B | ||
| BIIB | BIOGEN INC | 9.17 | 22.49B |
Related stock screener links
About ABIO
Company Profile
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The company is headquartered in Westminster, Colorado and currently employs 4 full-time employees. The company went IPO on 2000-07-21. The firm's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. The company is also evaluating options for development of its assets, including partnering and other strategic options.
Company Info
ARCA BIOPHARMA INC
10170 Church Ranch Way, Suite 100
Westminster COLORADO 80021 US
CEO: Michael R. Bristow
Employees: 4
Phone: 17209402200
ARCA BIOPHARMA INC / ABIO FAQ
What does ABIO do?
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The company is headquartered in Westminster, Colorado and currently employs 4 full-time employees. The company went IPO on 2000-07-21. The firm's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. The company is also evaluating options for development of its assets, including partnering and other strategic options.
What is the stock price of ARCA BIOPHARMA INC today?
The current stock price of ABIO is 2.4 USD. The price decreased by -4% in the last trading session.
What is the dividend status of ARCA BIOPHARMA INC?
ARCA BIOPHARMA INC (ABIO) has a dividend yield of 67.21%. The yearly dividend amount is currently 0.
What is the ChartMill rating of ARCA BIOPHARMA INC stock?
ABIO has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for ABIO stock?
ARCA BIOPHARMA INC (ABIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.5).
Would investing in ARCA BIOPHARMA INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ABIO.
ABIO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ABIO. When comparing the yearly performance of all stocks, ABIO is a bad performer in the overall market: 75.71% of all stocks are doing better.
ABIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABIO. While ABIO has a great health rating, there are worries on its profitability.
ABIO Financial Highlights
Over the last trailing twelve months ABIO reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS decreased by -13.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.27% | ||
| ROE | -22.1% | ||
| Debt/Equity | 0 |